胃癌肿瘤微环境中免疫细胞浸润与治疗抵抗

黄 玉甜1, 沈存 芳*2
1、青海大学
2、青海大学附属医院

摘要


胃癌（Gastric cancer，GC）是全球范围内发病率和死亡率较高的恶性肿瘤之一，其治疗抵抗和复发是临床面临的主要挑战。近年来，肿瘤微环境（tumor microenvironment TME）在胃癌发生、发展和治疗抵抗中的作用备受关注。肿瘤微环境由多种细胞成分及非细胞成分构成一个复杂的动态生态系统。在胃癌中，免疫细胞浸润在抗肿瘤免疫和免疫逃逸中扮演着双重角色，促进免疫逃逸和治疗抵抗。针对肿瘤微环境正在临床试验中展现出潜在的应用前景。重点探讨免疫细胞浸润与治疗抵抗的机制，有助于发掘靶向肿瘤微环境的治疗策略及其临床转化潜力。

关键词


胃癌；肿瘤微环境；免疫细胞；治疗抵抗

全文:

PDF


参考


[1]Machlowska J, Baj J, Sitarz M, et al. Gastric Cancer: Epidemiology, Risk Factors, Classification, Genomic Characteristics and Treatment Strategies [J]. International journal of molecular sciences, 2020, 21(11).

[2]Dingtian L, Jing Z, Shuiliang R, et al. Overcoming immunotherapy resistance in gastric cancer: insights into mechanisms and emerging strategies [J]. 2025, 16(1).

[3]Ricci J-E. Tumor-induced metabolic immunosuppression: Mechanisms and therapeutic targets [J]. Cell Reports, 2025, 44(1): 115206.

[4]Wang Q, Shao X, Zhang Y, et al. Role of tumor microenvironment in cancer progression and therapeutic strategy [J]. Cancer medicine, 2023, 12(10): 11149-65.

[5]Zeng D, Li M, Zhou R, et al. Tumor Microenvironment Characterization in Gastric Cancer Identifies Prognostic and Immunotherapeutically Relevant Gene Signatures [J]. Cancer immunology research, 2019, 7(5): 737-50.

[6]Guanjun L, Xiaohan L, Chunhui G, et al. Mutual exclusivity and co-occurrence patterns of immune checkpoints indicate NKG2A relates to anti-PD-1 resistance in gastric cancer [J]. 2024, 22(1).

[7]Liu Y, Altreuter J, Bodapati S, et al. Predicting patient outcomes after treatment with immune checkpoint blockade: A review of biomarkers derived from diverse data modalities [J]. Cell genomics, 2024, 4(1): 100444.

[8]Li J, Sun J, Zeng Z, et al. Tumour-associated macrophages in gastric cancer: From function and mechanism to application [J]. Clinical and translational medicine, 2023, 13(8): e1386.

[9]Forsthuber A, Aschenbrenner B, Korosec A, et al. Cancer-associated fibroblast subtypes modulate the tumor-immune microenvironment and are associated with skin cancer malignancy [J]. Nature Communications, 2024, 15(1): 9678.

[10]Geng X, Chen H, Zhao L, et al. Cancer-Associated Fibroblast (CAF) Heterogeneity and Targeting Therapy of CAFs in Pancreatic Cancer [J]. Frontiers in cell and developmental biology, 2021, 9: 655152.

[11]Sun H, Wang X, Wang X, et al. The role of cancer-associated fibroblasts in tumorigenesis of gastric cancer [J]. Cell death & disease, 2022, 13(10): 874.

[12]Wang Y, Li J, Nakahata S, et al. Complex Role of Regulatory T Cells (Tregs) in the Tumor Microenvironment: Their Molecular Mechanisms and Bidirectional Effects on Cancer Progression [J]. International journal of molecular sciences, 2024, 25(13).

[13]Yang Q, Guo N, Zhou Y, et al. The role of tumor-associated macrophages (TAMs) in tumor progression and relevant advance in targeted therapy [J]. Acta pharmaceutica Sinica B, 2020, 10(11): 2156-70.

[14]Liston A, Aloulou M. A fresh look at a neglected regulatory lineage: CD8+Foxp3+ Regulatory T cells [J]. Immunology Letters, 2022, 247: 22-6.

[15]康瑾，薛凯凯，范雅荣，et al. Legumain在肿瘤微环境中的作用[J].2022，44（9）：1830-7.

[16]Giles J R, Globig A-M, Kaech S M, et al. CD8+ T cells in the cancer-immunity cycle [J]. Immunity, 2023, 56(10): 2231-53.

[17]Tsutsumi C, Ohuchida K, Katayama N, et al. Tumor-infiltrating monocytic myeloid-derived suppressor cells contribute to the development of an immunosuppressive tumor microenvironment in gastric cancer [J]. 2024, 27(2): 248-62.

[18]Luo D, Zhou J, Ruan S, et al. Overcoming immunotherapy resistance in gastric cancer: insights into mechanisms and emerging strategies [J]. Cell death & disease, 2025, 16(1): 75.

[19]Luo D, Zhou J, Ruan S, et al. Overcoming immunotherapy resistance in gastric cancer: insights into mechanisms and emerging strategies [J]. 2025, 16(1): 75.

[20]Gerard C L, Delyon J, Wicky A, et al. Turning tumors from cold to inflamed to improve immunotherapy response [J]. Cancer Treatment Reviews, 2021, 101: 102227.

[21]Yi M, Zheng X, Niu M, et al. Combination strategies with PD-1/PD-L1 blockade: current advances and future directions [J]. Molecular cancer, 2022, 21(1): 28.

[22]Gravina A, Pellegrino R, Esposito A, et al. The JAK-STAT Pathway as a Therapeutic Strategy in Cancer Patients with Immune Checkpoint Inhibitor-Induced Colitis: A Narrative Review [J]. 2024, 16(3).

[23]Yu T, Jiao J, Wu M J F I I. CAR-T cells in the treatment of multiple myeloma: an encouraging cell therapy [J]. 2025, 16: 1499590.


Refbacks

  • 当前没有refback。